Focused On-demand Library for Biogenesis of lysosome-related organelles complex 1 subunit 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TDH9

UPID:

BL1S5_HUMAN

Alternative names:

Protein Muted homolog

Alternative UPACC:

Q8TDH9; B4DVM2; Q0VDJ6; Q0VDJ7; Q5THS1; Q68D56; Q8N5F9; Q9NU16

Background:

Biogenesis of lysosome-related organelles complex 1 subunit 5, also known as Protein Muted homolog, plays a pivotal role in the formation of lysosome-related organelles. It is a component of the BLOC-1 complex, essential for the biogenesis of platelet dense granules and melanosomes. This protein is involved in vesicle trafficking, targeting membrane protein cargos for delivery into neurites and nerve terminals, and is associated with SNARE proteins in neurite extension.

Therapeutic significance:

Hermansky-Pudlak syndrome 11, a disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects, is caused by variants affecting this gene. Understanding the role of Biogenesis of lysosome-related organelles complex 1 subunit 5 could open doors to potential therapeutic strategies for this syndrome.